Literature DB >> 9389732

Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.

S A Buechner1, M Wernli, T Harr, S Hahn, P Itin, P Erb.   

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer in humans, and although metastasis rarely occurs, the tumor cells are nevertheless able to invade and destroy the surrounding tissue. Intralesional injection of IFN-alpha has been found to be highly effective in inducing BCC regression by an unknown mechanism. We show that in untreated patients, BCC cells express CD95 ligand, but not the receptor, which may allow tumor expansion by averting the attack of activated CD95 receptor-positive lymphoid effector cells. The CD95 ligand of BCC cells is functional as CD95-positive cells incubated on BCC cryosections become apoptotic and are lysed. In IFN-alpha-treated patients BCC cells express not only CD95 ligand but also CD95 receptor, whereas the peritumoral infiltrate that mainly consists of CD4+ T cells predominantly contains CD95 receptor and only few CD95 ligand-positive cells. Thus, in treated patients BCC most likely regresses by committing suicide through apoptosis induction via CD95 receptor-CD95 ligand interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389732      PMCID: PMC508472          DOI: 10.1172/JCI119814

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

Review 1.  Cell death mechanisms and the immune system.

Authors:  P Golstein; D M Ojcius; J D Young
Journal:  Immunol Rev       Date:  1991-06       Impact factor: 12.988

2.  Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes.

Authors:  K Sayama; S Yonehara; Y Watanabe; Y Miki
Journal:  J Invest Dermatol       Date:  1994-09       Impact factor: 8.551

3.  Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.

Authors:  S Chimenti; K Peris; S Di Cristofaro; M C Fargnoli; G Torlone
Journal:  Dermatology       Date:  1995       Impact factor: 5.366

4.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

Review 5.  Apoptosis in the pathogenesis and treatment of disease.

Authors:  C B Thompson
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

6.  Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha.

Authors:  J Rodríguez-Villanueva; T J McDonnell
Journal:  Int J Cancer       Date:  1995-03-29       Impact factor: 7.396

Review 7.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

Review 8.  Mechanism and biological significance of CD4-mediated cytotoxicity.

Authors:  S Hahn; R Gehri; P Erb
Journal:  Immunol Rev       Date:  1995-08       Impact factor: 12.988

9.  Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines.

Authors:  M Oishi; K Maeda; S Sugiyama
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

View more
  11 in total

1.  Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.

Authors:  Asuka Nanbo; Kaori Inoue; Kumi Adachi-Takasawa; Kenzo Takada
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

2.  A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells.

Authors:  Yi Huang; Erin R Hager; Dawn L Phillips; Valerie R Dunn; Amy Hacker; Benjamin Frydman; John A Kink; Aldonia L Valasinas; Venodhar K Reddy; Laurence J Marton; Robert A Casero; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

Review 3.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation.

Authors:  Martina C Herwig-Carl; Karin U Loeffler
Journal:  Ocul Oncol Pathol       Date:  2019-08-28

Review 5.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies.

Authors:  Ignacio Melero; Eduardo Castanon; Maite Alvarez; Stephane Champiat; Aurelien Marabelle
Journal:  Nat Rev Clin Oncol       Date:  2021-05-18       Impact factor: 66.675

6.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

7.  STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Authors:  Jason R Baird; Zipei Feng; Hong D Xiao; David Friedman; Ben Cottam; Bernard A Fox; Gwen Kramer; Rom S Leidner; R Bryan Bell; Kristina H Young; Marka R Crittenden; Michael J Gough
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

8.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Authors:  Lorenzo Anasagasti-Angulo; Yanelda Garcia-Vega; Silvia Barcelona-Perez; Pedro Lopez-Saura; Iraldo Bello-Rivero
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

9.  Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein.

Authors:  Annika Vogt; Pao-Tien Chuang; Jennifer Hebert; Jimmy Hwang; Ying Lu; Levy Kopelovich; Mohammad Athar; David R Bickers; Ervin H Epstein
Journal:  J Exp Med       Date:  2004-03-15       Impact factor: 14.307

Review 10.  Type I interferons: key players in normal skin and select cutaneous malignancies.

Authors:  Aimen Ismail; Nabiha Yusuf
Journal:  Dermatol Res Pract       Date:  2014-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.